August 25, 2020 | ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the acquisition of CerSci Therapeutics, a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for neurological conditions, including non-opioid therapies for acute and chronic pain. Under the terms of the agreement, ACADIA acquired all of the outstanding shares of CerSci for $52.5 million, primarily in ACADIA stock. The transaction closed on August 24, 2020. CerSci shareholders may also receive up to $887 million in development, commercialization, and sales milestones in addition to tiered royalties in the mid-single digits based on annual net sales.
Back to top
July 23, 2020 | Globe Newswire
Neumentum announced updates related to development of its two non-opioid analgesic candidates, NTM-001 and NTM-006.
EDITOR'S NOTE: Expanesthetics is developing a class of non-opiate analgesics toward different indications. Neumentum’s development shows the industry and regulatory progress being made in this space.
Back to top
June 27, 2020 | The Carlyle Group
The Carlyle Group purchases a significant stake in Piramal Pharma, a newly reorganized group within Piramal Enterprises, one of the world's three largest inhaled anesthesia companies.
Back to top
May 12, 2020 | BJS Society
The COVIDâ€19 pandemic has disrupted routine hospital services globally. This study estimated the total number of adult elective operations that would be cancelled worldwide during the 12 weeks of peak disruption due to COVIDâ€19.
Back to top
April 30, 2020 | Alpha Street
Baxter Healthcare, the world leader in inhaled anesthesia, comments on its performance for the first quarter of 2020. In addition to reporting financial performance and ongoing plans, they make two important comments related to inhaled anesthesia. First, they announce declines of inhaled anesthesia sales in the first quarter and expected decreased sales in the second quarter all related to a decline in surgery due to COVID-19. Second, they note that their inhaled anesthesia products are among their higher-margin products. Third, they note that declines in financial performance from their Advanced Surgery portfolio (which contains inhaled anesthesia) have been and are expected to be offset by revenue and other gains elsewhere in their operations.
Back to top
